Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics 10.26.2022

Seres Therapeutics Announces Positive Topline Results From SER-109 Phase 3 ECOSPOR III Study In Recurrent C. Difficile Infection

Seres Therapeutics 08.13.2020

Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors

Seres Therapeutics 03.23.2020

Seres Therapeutics Appoints Stephen Berenson to its Board of Directors

Seres Therapeutics 08.06.2019

Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantationse

Seres Therapeutics 06.19.2019

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

Seres Therapeutics 03.11.2019

Seres Therapeutics Announces Chief Executive Officer Transition

Seres Therapeutics 01.15.2019

Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis

Seres Therapeutics 01.03.2019

Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis

Seres Therapeutics 12.04.2017

Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology

Seres Therapeutics 11.14.2017

Loading